Conservative strategy in infantile fibrosarcoma is possible: The European paediatric Soft tissue sarcoma Study Group experience

Daniel Orbach, Bernadette Brennan, Angela De Paoli, Soledad Gallego, Peter Mudry, Nadine Francotte, Max Van Noesel, Anna Kelsey, Rita Alaggio, Dominique Ranchère, Gian Luca De Salvo, Michela Casanova, Christophe Bergeron, Johannes H M Merks, Meriel Jenney, Michael C G Stevens, Gianni Bisogno, Andrea Ferrari

Research output: Contribution to journalArticlepeer-review


Background Infantile fibrosarcoma (IFS) is a very rare disease occurring in young infants characterised by a high local aggressiveness but overall with a favourable survival. To try to reduce the total burden of therapy, the European pediatric Soft tissue sarcoma Study Group has developed conservative therapeutic recommendations according to initial resectability. Material and methods Between 2005 and 2012, children with localised IFS were prospectively registered. Initial surgery was suggested only if possible without mutilation. Patients with initial complete (IRS-group I/R0) or microscopic incomplete (group II/R1) resection had no further therapy. Patients with initial inoperable tumour (group III/R2) received first-line vincristine-actinomycin-D chemotherapy (VA). Delayed conservative surgery was planned after tumour reduction. Aggressive local therapy (mutilating surgery or external radiotherapy) was discouraged. Results A total of 50 infants (median age 1.4 months), were included in the study. ETV6-NTRK3 transcript was present in 87.2% of patients where investigation was performed. According to initial surgery, 11 patients were classified as group I, 8 as group II and 31 as group III. VA chemotherapy was first delivered to 25 children with IRS-III/R2 and one with IRS-II/R1 disease. Response rate to VA was 68.0%. Mutilating surgery was only performed in three cases. After a median follow-up of 4.7 years (range 1.9-9.0), 3-year event-free survival and overall survival were respectively 84.0% (95% confidence interval [CI] 70.5-91.7) and 94.0% (95% CI 82.5-98.0). Conclusions Conservative therapy is possible in IFS as only three children required mutilating surgery, and alkylating or anthracycline based chemotherapy was avoided in 71.0% of patients needing chemotherapy. VA regimen should be first line therapy in order to reduce long term effects.

Original languageEnglish
Pages (from-to)1-9
Number of pages9
JournalEuropean Journal of Cancer
Publication statusPublished - Apr 1 2016


  • Cancer
  • Chemotherapy
  • ETV6-NTRK3 transcript
  • Infant
  • Infantile fibrosarcoma
  • Newborn

ASJC Scopus subject areas

  • Cancer Research
  • Oncology


Dive into the research topics of 'Conservative strategy in infantile fibrosarcoma is possible: The European paediatric Soft tissue sarcoma Study Group experience'. Together they form a unique fingerprint.

Cite this